Pharmacyclics, Inc.  

(Public, NASDAQ:PCYC)   Watch this stock  
Find more results for PCYC
121.25
+0.21 (0.17%)
Sep 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 119.84 - 121.82
52 week 82.51 - 154.89
Open 120.01
Vol / Avg. 383,083.00/840,829.00
Mkt cap 9.37B
P/E 109.57
Div/yield     -
EPS 1.11
Shares 75.27M
Beta 0.75
Inst. own 75%
Sep 3, 2014
Pharmacyclics Inc at Robert W. Baird & Co. Inc Health Care Conference
Jul 31, 2014
Q2 2014 Pharmacyclics Inc Earnings Call
Jul 31, 2014
Q2 2014 Pharmacyclics Inc. Earnings Release
Jul 28, 2014
Pharmacyclics, Inc. FDA Full Approval - Corporate Call
Jun 24, 2014
Pharmacyclics Inc at JMP Securities Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin -32.79% 25.76%
Operating margin -32.92% 37.64%
EBITD margin - 38.49%
Return on average assets -18.22% 11.92%
Return on average equity -22.57% 15.06%
Employees 484 -
CDP Score - -

Address

995 E ARQUES AVE
SUNNYVALE, CA 94085-4521
United States - Map
+1-408-7740330 (Phone)
+1-408-7740340 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Pharmacyclics, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�s tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

Officers and directors

Robert W. Duggan Chairman of the Board, Chief Executive Officer
Age: 69
Bio & Compensation  - Reuters
Manmeet Soni Chief Financial Officer, Executive Vice President - Finance, Chief Accounting Officer, Treasurer
Age: 36
Bio & Compensation  - Reuters
Mahkam Zanganeh DDS Chief Operating Officer
Age: 43
Bio & Compensation  - Reuters
Rainer M. Erdtmann Senior Vice President - Investor Relations and Administration
Age: 50
Bio & Compensation  - Reuters
Urte Gayko Ph.D. Senior Vice President - Regulatory
Age: 42
Bio & Compensation  - Reuters
Sumita Ray Chief Compliance Officer, Associate General Counsel - Healthcare Law
Bio & Compensation  - Reuters
Gregory W. Hemmi Ph.D. Vice President - Chemical Operations
Age: 47
Bio & Compensation  - Reuters
Darrin Beaupre MD, PhD. Vice President - Clinical Medicine and Early Development
Bio & Compensation  - Reuters
Betty Y. Chang Ph.D. Vice President - Research/Biology
Bio & Compensation  - Reuters
Fong Wang Clow Vice President - Biostatistics, Programming, and Data Management
Age: 55
Bio & Compensation  - Reuters